Thomas R.P. et al., noted that in newly diagnosed GBM patients treated with Plerixafor—a CXCR4 inhibitor, this was well tolerated in addition to Bevacizumab and improved local control of tumor recurrences [258]. Here, CXCR4 is linked to neoplasm.